These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Prevention of HLA antibody formation in patients with hemato-oncologic diseases by using leukocyte depleted blood preparations]. Adamzik ID, Jin J, Sachs V, Thomsen H. Infusionsther Transfusionsmed; 1995 Feb; 22(1):9-13. PubMed ID: 7727966 [Abstract] [Full Text] [Related]
3. [Platelet alloimmunization in patients with oncologic blood disorders treated with multiple transfusions: prospective study in adults and children]. Pereira J, Bronfman L, Bertín P, Marzouka E, Hidalgo P, Amaya S, Mezzano D. Rev Med Chil; 1997 Nov; 125(11):1305-12. PubMed ID: 9609051 [Abstract] [Full Text] [Related]
4. Use of leukocyte-depleted platelet concentrates for the prevention of refractoriness and primary HLA alloimmunization: a prospective, randomized trial. van Marwijk Kooy M, van Prooijen HC, Moes M, Bosma-Stants I, Akkerman JW. Blood; 1991 Jan 01; 77(1):201-5. PubMed ID: 1984797 [Abstract] [Full Text] [Related]
5. [Production of leukocyte-poor thrombocyte concentrates: results with a new kind of filter system]. Böck M, Salat C, Greither L, Heim MU, Weindler R, Bilas A, Mempel W. Beitr Infusionsther; 1990 Jan 01; 26():103-5. PubMed ID: 1703804 [Abstract] [Full Text] [Related]
6. [Prevention of HLA-alloimmunization of recipients of platelet concentrates]. Kuntz BM, Wollenhaupt HJ, Brüster HT. Beitr Infusionsther; 1991 Jan 01; 28():209-12. PubMed ID: 1725621 [Abstract] [Full Text] [Related]
15. Prevention of HLA alloimmunization: role of leukocyte depletion and UV-B irradiation. Snyder EL. Yale J Biol Med; 1990 Jun 01; 63(5):419-27. PubMed ID: 2293501 [Abstract] [Full Text] [Related]
17. Prevention of platelet refractoriness due to HLA antibodies by administration of leukocyte-poor blood components. Eernisse JG, Brand A. Exp Hematol; 1981 Jan 01; 9(1):77-83. PubMed ID: 7238644 [Abstract] [Full Text] [Related]